← Allogene Therapeutics, Inc. (ALLO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Allogene Therapeutics, Inc. (ALLO)
Biological Products, (No Diagnostic Substances) · market cap $577M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Allogene Therapeutics (ALLO) is a clinical-stage biotech with 226 employees and a ~$618M market cap developing allogeneic (off-the-shelf) cell therapies for hematologic malignancies. Its pipeline centers on Fludarabine (Phase 2, Large B-cell Lymphoma) and ALLO-647 (Phase 2, R/R LBCL, CLL, and SLL). The company has generated zero product revenue since 2022 and carries only ~$30.3M in cash — roughly 7 months of runway — against a persistent burn rate exceeding $150M annually.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-08-24 (est.)Phase 2 · ALLO-647imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ALLO-647 | Phase 2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma |
Price & technical context
3-month
-26.0%
6-month
-39.8%
12-month
+24.2%
52-wk range
$1.05–$3.06
vs 50-day MA
-18.0%
vs 200-day MA
-22.7%
Realized vol
84.9%
Max drawdown
-70.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALLO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.